Quick Navigation


Chromium is an essential mineral. It regulates glucose metabolism and insulin sensitivity. Supplementing more chromium than the body needs does not produce reliable results, but it may be associated with minor benefits to diabetics.

Our evidence-based analysis on chromium features 184 unique references to scientific papers.

Research analysis led by and reviewed by the Examine team.
Last Updated:

Easily stay on top of the latest nutrition research

Become an Examine Member to get access to all of the latest nutrition research:

  • Unlock information on 400+ supplements and 600+ health topics.
  • Get a monthly report summarizing studies in the health categories that matter specifically to you.
  • Access detailed breakdowns of the most important scientific studies.

Try FREE for 14 days

Research Breakdown on Chromium

1Sources and Structure


Chromium is an essential mineral in the human diet and a common dietary supplement used to enhance insulin sensitivity and improve diabetes.[2]

Chromium can be found in:

  • Bovine colostrum (in the form of a zinc-rich chromodulin oligopeptide, with one chromium atom per four amino acids[3][4]) yielding 220µg chromium per 1,035g of protein (193ng/g protein)[3]

  • Skimmed milk, at a concentration of 252µg chromium per 1,172g of protein (215ng/g protein)[3]


Chromium itself is a dietary mineral and an element (Cr) with multiple valences. The fully-oxidized form of chromium (Cr(VI)), which is hexavalent (+6 oxidation state), is highly toxic and employed in a variety of industrial applications[5]. Given the high degree of toxicity, hexavalent chromium is never used as a supplement. Supplemental forms of chromium include divalent (Cr(II)) or trivalent (Cr(III)), the latter being the most stable form.[2]


At least 0.005–0.2mg (5-20µg) of dietary chromium is needed daily to prevent deficiency, and the recommended intake is 21-25µg for women and 25-35µg for men daily with the 18-45 age bracket requiring amounts at the higher end of this range.[6] Woman of all ages who are breast-feeding require 45µg of chromium per day.[6] Children have a recommended intake of 11µg (1-3 years old) or 15µg (4-8 years old).[6]

Standard circulating chromium concentrations in a non-deficient state have been measured in the range of 2.8–45 µg/L in whole blood and 0.12-2.1 µg/L in serum.[7]


A deficiency of chromium can be induced with long-term total parenteral nutrition (TPN) lacking chromium, and has been reversed with supplementation of 150µg daily added to the TPN in one case study[8] and 250µg daily for 2 weeks followed by a maintenance dose of 20µg daily for 18 months in another.[9] The main symptoms of deficiency in these cases appeared to be significantly impaired glucose tolerance and insulin sensitivity associated with weight loss, as well as neuropathy and encephalopathy which were reversible upon replenishment of chromium.[9][8]

Severe chromium deficiency is associated with type-I diabetic-like symptoms (impaired glucose tolerance and weight loss) as well as neuropathy, and can be reversed by administering chromium.

Subclinical deficiencies in chromium are associated with insulin resistance, since chromium concentrations have been found to be lower in diabetics relative to controls[10] (the evidence is mixed for gestational diabetes, however[11][12]). Chronic high-sugar diets (35% of daily calories) have been noted to accelerate urinary chromium losses,[13] although diets composed of high glycemic index foods failed to acutely influence urinary chromium elimination in healthy subjects despite showing a trend over six days.[14] 

This acclerated urinary chromium loss is thought to occur via release of chromodulin from insulin-sensitive cells into the bloodstream followed by its elimination in the urine.[15] Chromodulin is a peptide which exists inside of cells. When combined with chromium taken into cells from the bloodstream, it amplifies insulin signaling by binding to insulin-stimulated insulin receptors.[15] Chromodulin binds chromium ion with very high affinity, forming a complex that can only be separated under non-physiological conditions. Once insulin levels drop, however, the insulin receptors no longer need to be sensitized, so the entire complex must be eliminated as a whole.[15] [16] This hypothesis is supported by detection of chromodulin in the urine[17] and its tight correlation with insulin secretion rates and exposure under nonsupplemental conditions.[17][18][19]

Insulin resistant states may be associated with lower chromium levels, although not low enough to be considered a legitimate deficiency. This may be related to an increase in urinary chromium losses which seems to be caused by a diet high in sugars.

Urinary chromium concentrations are elevated with endurance exercise (a five-fold increase following two hours of running, but only two-fold over the course of the day) in a manner that is not related to an increase in serum insulin and not related to an increase in any other urinary ion.[19] This situation, despite no increase in insulin levels, is known to require higher glucose uptake in muscle tissue sustained by higher release of glucose from the liver.[20]


Trivalent chromium (the type found in supplements), appears to have toxic effects at concentrations above 20µg/mL in the serum or cells; this toxicity is associated with oxidative damage to DNA.[21] This is the same mechanism by which hexavalent chromium is toxic, except the latter is toxic at much lower concentrations,[22] particularly after inhalation during occupations involving the handling of hexavalent chromium.[23][5]

1.6Variants and Formulations

Chromium picolinate is a term referring to chromium in the trivalent state (Cr(III)) which is bound to three molecules of picolinic acid, a structural analogue of niacin. This form of chromium is highly stable[24] aside from possible acid induced degradation, which would remove a picolinate molecule and lead to two chromium ions binding together.[25] The picolinate ligands are in such a position that the Cr(III) can be reduced into Cr(II) in cell culture without losing the picolinate,[26] a property that seems to be unique to picolinate relative to other supplemental forms (chloride and nicotinate) and is thought to underlie possible carcinogenic properties at high concentrations.[27]

Chromium picolinate is thought to be physiologically inactive until it releases free chromium,[27] suggesting that it serves as a chromium prodrug.

Chromium picolinate is a readily absorbed prodrug for chromium that is also highly stable when outside of the body (in processing and in storage).

Chromium is known to be present in yeast, where it plays a major physiological role.[28][29] Within yeast cells is 'glucose tolerance factor' (GTF)[30], which was first derived from brewer's yeast.[31] GTF can be purified from yeast after methanolic extraction and subsequent filtration, yielding a set of molecules 1,000 and 3,500 Da in size.[32][33] The major active components in this set of molecules are thought to be trivalent chromium nicotinic acid along with some amino acids (glycine, L-cysteine, and glutamic acid).[34] Dietary intake of yeast seems to confer some of the benefits of chromium supplementation, probably due to GTF and chromium intake.[30]

Chromium from yeast is thought to be chromium nicotinic acid, although there may be other forms of chromium in yeast that have not yet been found.

Chromium nicotinic acid (also known as chromium polynicotinate) is chromium complexed with nicotinic acid (Niacin or Vitamin B3), and is reported to have cholesterol reducing effects.[35][36] The studies in which cholesterol is reduced do not necessarily find glucose metabolism benefits,[35][36] suggesting that it is the niacin that is causing these effects.

Chromium nicotinic acid is a form of chromium bound to niacin (vitamin B3), which has cholesterol-lowering effects. Because studies noting reduced cholesterol failed to show effects on glucose metabolism, the cholesterol-lowering effects of this chromium compound may be due to niacin.

Chromium dinicocysteinate (CDNC) is a complex of the chromium ion with the amino acid L-cysteine. One study comparing 400µg of chromium as CDNC against 400µg of chromium as picolinate found improvements in insulin levels and sensitivity only with CDNC.[37]

Chromium dinicocysteinate (CDNC) is a form of chromium bound to L-cysteine. While preliminary evidence suggests that it is effective, the body of evidence is not large enough to conclude its efficacy relative to chromium picolinate or brewer's yeast.

2Molecular Targets


One of the major mechanisms thought to be related to chromium supplementation involves modulation of the insulin signalling pathway.[38] This was first discovered when a low molecular weight chromium-binding oligopeptide was identified that augmented the effects of insulin on glucose oxidation.[39] Also called LMCr or Chromodulin[40], this oligopeptide is produced in the liver of rats following chromium injections[41] and has a mass of approximately 1500 kDa.[40][42]

It was found that chromodulin increased insulin signalling in the presence of insulin 5-8 times higher than baseline activity, without affecting signalling in the absence of insulin.[43] Depleting chromodulin of chromium ablates the activity,[43] which positively correlates with the chromium content of the peptide. Also, other minerals failed to replicates its effects.[44] 

Ultimately, chromodulin increases autophosphorylation of the insulin receptor. Insulin receptor signalling requires that insulin or a mimetic (something that behaves like insulin) binds to the extracellular α-subunit of the receptor[45] which allows the intracellular β-subunit to be autophosphorylated.[45] Chromodulin appears to act intracellularly at the β-subunit of the insulin receptor.[15]

The chromium-dependent functions of chromodulin are likely the biological reason chromium is an essential mineral[46], although chromium's essential nature has recently come into dispute.[47]

An oligopeptide known as chromodulin binds to chromium, and requires chromium to augment insulin receptor signaling. This may be one of the biological reasons chromium is arguably an essential nutrient, and deficiencies in chromium are thought to impair chromodulin's ability to enhance insulin signalling.


Adenosine Monophosphate Kinase (AMPK) is a key sensor of cellular energy status, constantly monitoring ATP levels to maintain metabolic homeostasis. AMPK is activated during low energy states (signified by increased AMP to ATP ratios) where it coordinates fatty acid and glucose metabolism in an anti-obesity and anti-diabetic manner.[48] When activated, AMPK suppresses anabolic pathways such as protein, triglyceride and fatty acid synthesis while activating catabolic pathways such as glycolysis and fatty acid oxidation to augment ATP production.[49] 

Chromium (trivalent with D-phenylalanine) has been noted to activate AMPK at its catalytic site (Thr172) in cardiomyocytes and skeletal muscle cells at 25μM, suggesting that organic chromium complexes may be novel activators of the AMPK pathway.[50]

Chromium in complex with D-phenylalanine has been implicated as an AMPK activator. It is not clear whether this effect is common to all types of chromium complexes, or may be unique to this particular form. Thus, it is also not clear whether this effect is relevant to oral chromium supplementation.



Absorption of dietary chromium is inversely correlated with intake, varying from 0.4% to 2.0%, with the more efficient absorption (2%) at lower dietary intake of around 10µg in adult humans.[51] This declines to around 0.5% when dietary intake reaches 40 µg where it seems to bottom-out, as chormium intake in the range of 40-240 µg has an absorption of around 0.4%.[51][52]

Chromium absorption is influenced by a number of dietary factors. In rats, chromium absorption appears to be hindered by phytate coingestion, which prevents transport and absorption across the intestines.[53] Zinc deficiency has been shown to increase chromium absorption, which is increased in zinc-deficient rats and reduced by supplemental zinc,[54] suggesting that these two minerals may compete for absorption. Chromium absorption in rats is also enhanced by oxalate, an organic acid found in many vegetables and grains.[53] Although informative, care must be taken when extrapolating results from rat studies to humans, as recent studies have noted that absorption of dietary chromium in humans is significantly greater than rats for a number of chromium complexes tested.[55] 

Amino acids appear to enhance absorption of chromium from the diet as they form complexes that enhance absorption by reducing the tendency of chromium to precipitate in the alkaline intestinal fluid.[2] Chromium absorption in humans is also significantly increased in the presence of ascorbic acid and nicotinic acid.[2]

Percentage-wise, chromium is not well absorbed, and dietary intake is inversely correlated with absorption. The most efficient absorption (around 2%) occurs with less (around 10 μg), rather than more (40+ μg) chromium, which is absorbed in the 0.4-0.5% range. Chromium absorption is also affected by the presence of dietary factors such as amino acids, minerals such as zinc, and certain organic acids.


In type II diabetics, 1,000µg daily chromium supplementation (as chromium picolinate) was sufficient to bring fasting chromium levels in serum from 2.40 ± 0.19 vs. 0.16 ± 0.05 ng/dL at baseline after 12 weeks and 2.62 +/- 0.09 ng/dL vs. 0.17 +/- 0.04 ng/dL at baseline after 24 weeks supplementation.[56]


Transferrin is a transport protein in serum known to bind to minerals (notably iron). It has been noted to have affinity for trivalent chromium,[57] binding two ions of chromium per transferrin molecule.[58][59] Transferrin is thought to donate chromium to the chromium-binding oligopeptide chromodulin.[60] Altough earlier studies suggested that chromodulin donates chromium to transferrin, this work was conducted at higher temperatures, which may have caused chromodulin degradation.[61] More recent studies have shown that chromodulin does not release chromium to transferrin, however.[60] Since transferrin releases ions within a cell after endocytosis,[62] it seems that chromodulin accepts and retains these ions from transferrin.

Transferrin is a protein known to transport many divalent and trivalent ions, including chromium. Following uptake by a cell, it can release free chromium ions which are then taken up by the chromium-binding oligopeptide chromodulin.


Supplementation of chromium results in increased urinary elimination of chromium.[56]

One rat study has noted that toxic levels of chromium (100µg/kg food intake) seem to bioaccumulate more with chromium chloride relative to chromium picolinate, due in part to a higher excretion rate seen with picolinate.[63] This was hypothesized to be due to the picolinate (picolinic acid), which has been noted to increase elimination of minerals such as zinc.[64]



Low doses of chromium picolinate in the food (providing 1ppm of chromium) of Long-Evans rats extended both median and maximal lifespan, which was associated with reduced age-related increases in glucose and insulin concentrations.[65] This was also supported by toxicity studies; chromium supplementation in rats at either 0.5ppm [66] or 7.7ppm (cited indirectly via review [67]) in drinking water was associated with longer lifespan relative to controls.

Chromium supplementation has been reported to improve glucose tolerance in the elderly.[68] When investigating only well-nourished elderly people, however, it seems that chromium is without effect, [69] suggesting that chromium supplementation may be associated with anti-aging effects in humans only in the context of dietary deficiency.

Chromium has been shown to have robust anti-aging effects in rats that were attributed to reduced age-associated increases in glucose and insulin levels. Limited studies in humans suggest that chromium may only confer anti-aging effects in the context of a dietary deficiency, however.


5.1Adrenergic Neurotransmission

Oral ingestion of chromium picolinate by rats for two weeks (100mg/kg in the diet, estimated 10mg/kg bodyweight) is able to increase brain concentrations of noradrenaline by 59.1% relative to a control diet.[70] The mechanism by which chromium is acting here is uncertain, although it has been hypothesized to be insulin-mediated;[71] insulin can cross the blood-brain barrier and increase synaptic noradrenaline concentrations by preventing its reuptake.[72]

5.2Serotonergic Neurotransmission

It is thought that chromium can desensitize signalling through the 5-HT2A serotonin receptor since it impairs the increase in cortisol normally seen with 5-HTP (a serotonin precursor) administration in rats (100mg/kg chromium picolinate in the diet) and humans (400µg as picolinate).[73]

It is thought that chromium can reduce serotonin signalling via the 5-HT2A receptors.

It is hypothesized that chromium sensitizes the hypothalamus in particular to the effects of insulin, thus affecting glucose metabolism. This can result in increased glycolysis (usage of glucose) and production of serotonin.[65] Higher serotonin activity correlates with increased insulin sensitivity in the periphery (at least in healthy subjects), which may in part account for chromium's effect on glucose utilization.[74]

It is thought that chromium is able to increase production of serotonin in the brain, which may lead to changes in how sugar is used by the body.

Chromium injections acutely and dose-dependently increase plasma tryptophan and brain serotonin concentrations (20-50mg/kg of chromium picolinate) in rats,[70] and 100mg/kg chromium picolinate in the rat diet (estimated 10mg/kg intake based on bodyweight) for two weeks increased free (but not total) tryptophan by 61.9% while also increasing serotonin by 38.5%.[70] This has been replicated elsewhere in rats fed chromium picolinate at the same dose,[73] however oral ingestion of 400µg chromium (as picolinate) in humans has failed to modify free or total plasma tryptophan concentrations.[73]

Rat studies demonstrate an increase in brain serotonin with oral chromium supplementation. Evidence for this effect in humans is weaker.

5.3Melatonergic Neurotransmission

Oral supplementation of chromium picolinate (estimated 10mg/kg based on rat bodyweight, and an estimated human equivalent of 2,000-3,000µg elemental chromium) significantly increases melatonin concentrations in the pineal gland, noted alongside a general increase in brain serotonin levels.[70] and an increase in synaptic noradrenaline (noradrenaline reuptake inhibitors tend to increase melatonin in the pineal gland[75]).

5.4Food Intake and Appetite

Several studies have suggested that chromium supplementation may promote reduced food intake and appetite in both human and animal subjects. A recent meta-analysis of 10 randomized, double-blind, placebo-controlled studies concluded that chromium picolinate had a relatively modest, but significant weight-loss inducing effect when compared to placebo[76], possibly suggesting an appetite-suppressing effect. The mechanism(s) associated with putative food intake suppressing effects of chromium are currently unknown, although it has been proposed to occur via neurotransmitters in the brain that control appetite and cravings.[73][77] 

This was confirmed in a recent study in overweight adult women who reported intense carbohydrate cravings (at least twice a week). Daily supplementation with 1,000μg chromium (as picolinate) over the course of eight weeks resulted in a greater reduction in food intake (25%) compared to placebo (8%).[78] Reduction in food intake was associated with decreased hunger and cravings, however macronutrient composition was unaffected and these changes were independent of any effects on insulin sensitivity.[78] In a parallel trial by the same research group, it was found that peripheral administration of chromium in rats (via IP injection) resulted in only a modest decrease in food intake, compared to a significant, dose-dependent decrease in food intake when administered centrally (directly into the brain).[78] Taken together, this work suggests that chromium supplementation may promote reduced food intake by affecting neurotransmitters in the brain that control appetite and cravings.

Chromium has been shown to promote reduced food intake in rats. This effect has also been demonstrated in human subjects, although it is not clear whether it may be specific to certain populations. Studies in rats suggest the food-intake reducing effects of chromium may occur via direct effects in the brain, via regulation of neurotransmitters that control appetite and feeding behavior.

In atypical depression patients (which is a particular subset of depression associated with higher food intake, sleep, and mood reactivity[79]), 600μg chromium as picolinate for eight weeks failed to significantly influence the majority of depressive symptoms. However, there were significant improvements in carbohydrate cravings and food intake with a greater effect in those reporting larger carbohydrate cravings at baseline.[77] In persons with binge eating disorder, the rate of decline in binging frequency was greater with 1,000μg chromium than placebo and 600μg, although the overall reduction failed to reach statistical significance.[80]

Chromium may promote reduced food intake in those afflicted with abnormally high appetite or carbohydrate cravings that often co-occur with depression or binge-eating disorders. It may also promote reduced food intake in those with atypically strong cravings in the absence of any pathological diagnosis.


Supplementation of 1,000µg chromium (as picolinate) for 12 weeks to elderly adults with organic memory decline failed to exert antidepressive effects as assessed by the Geriatric Depression Scale.[81]

In a pilot study (no placebo control) for persons with rapid-cycling bipolar disorder, only a minority of subjects that received 600-800µg chromium daily alongside their standard medication exhibited less depressive symptoms (30% responders on the HAMD, 39% on MADRS) after three weeks.[82] In contrast, a series of case studies in dysthymic disorder have noted that chromium may significantly reduce depressive symptoms.[83] Moreover, a pilot study in atypical depression noted that 600µg chromium (picolinate) was better than placebo at reducing symptoms of depression in 70% (7/10) of subjects [84]. Although promising, it should also be noted that whole-group benefits of chromium supplementation in this study failed to reach statistical significance, as assessed by SCL-90 and HAM-D).[84]

Although Chromium has shown promise in reducing depressive symptoms, its efficacy may be limited to particular disorders, such as dysthymia or atypical depression.

5.6Memory and Learning

Supplementation of chromium (picolinate) providing 1,000µg elemental chromium over 12 weeks in older adults with evidence of memory decline failed to improve memory (short, long, and recognition memory) but reduced inclusion errors during testing.[81] This reduction in inclusion errors was associated with increased activity (assessed by fMRI) in the right thalamic, temporal, and posterior parietal regions as well as the bilateral frontal regions during a working memory task.[81]

6Cardiovascular Health

6.1Cardiac Tissue

Suboptimal chromium levels have recently been identified as a possible risk factor for cardiovascular disease. Low chromium concentrations in the toenail (which builds up minerals from the body similar to hair) is associated with an increased risk of nonfatal myocardial infarction.[85] In a double-blind, placebo-controlled crossover study, type II diabetics who supplemented with 1,000µg chromium (as picolinate) daily for three months exhibited a shortened QTc interval.[86] QTc interval prolongation, which has been linked to impaired glucose homeostasis in type II diabetics, is a powerful predictor of caridiac death [87][88], suggesting that chromium supplementation may exhibit a moderate cardioprotective effect by promoting improved glucose homeostasis. Consistent with this, benefits of three months of supplementation were carried over for an additional three months without supplementation and occurred concurrently with reductions in serum insulin levels. This effect occurred independently of any changes in glucose or HbA1c levels and heart rate was unaffected.[86]

Low chromium levels have been linked to increased risk for cardiovascular disease in men. Chromium supplementation has been shown to shorten the QTc interval in type II diabetics, which is suggestive of a cardioprotective effect.

6.2Red Blood Cells

The concentration of chromium in red blood cells (RBCs) tends to be higher (3.84–69.2nM) than that in serum (2.3–40.3nM).[89]

RBC membrane abnormalities are prevalent in diabetes and associated with oxidative damage.[90] When RBCs were treated with high glucose in vitro to simulate a diabetic state, they were structurally protected by chromium chloride,[91] suggesting that chromium may confer a layer of protection against erythrocyte oxidative damage during impaired glucose homeostasis.


Chromium does not appear to effect triglycerides. In a recent meta-analysis of five trials that evaluated the effects of 250μg or greater chromium supplementation for a period of over three months, the authors failed to find any effect on triglycerides relative to placebo.[92]


A meta-analysis of chromium supplementation (250µg or more) in type II diabetics for a period of greater than three months[92] failed to find any evidence of significant improvements in total cholesterol, HDL cholesterol, LDL cholesterol, or vLDL cholesterol relative to placebo.

7Interactions with Glucose Metabolism


Supplementation of 1,000µg chromium (as picolinate) in two divided doses for 24 weeks in type II diabetics failed to significantly influence hepatic glucose production relative to placebo.[56] (Hepatic glucose production is often pathologically elevated in diabetics[93])

Chromium does not affect gluconeogenesis, a process where glucose is produced in the liver from non-carbohydrate carbon substrates that is pathologically increased in diabetics.

When medicated diabetics consumed 200µg chromium (as chloride) added to a milk powder product daily for 16 weeks, blood glucose and insulin levels were significantly reduced while insulin sensitivity improved.[94] The results of this study were somewhat gender-specific however, as significant improvements in the aforementioned markers of glucose homeostasis occurred in male subjects only.[94]

7.2Insulin Receptor

Chromodulin is an endogenous oligopeptide[42] containing chromium which positively mediates signalling of the insulin receptor when in the presence of insulin.[39] Injecting of chromium (as potassium chromate) into rats increases urinary and fecal concentrations of this oligopeptide.[95] However, urinary chromodulin does not appear to be saturated under basal conditions, implying that more chromium could be bound to the oligopeptide.[95] Since the potency of chromodulin in enhancing insulin signaling correlates with the amount of chromium bound to it,[44] and injections of potassium chromate in rats result in rapid association with chromodulin,[61][96] it is possible that increased dietary chromium could increase the activity of this oligopeptide.

Operating under the assumption that typical dietary chromium intakes are insufficient to saturate chromodulin, chromium supplementation could theoretically enhance insulin signaling by increasing chromium-chromodulin association.

In studies using trivalent chromium, there appears to be an increase in insulin receptor kinase activity (in the presence of insulin) when 1-10μM chromium is added to mammalian cell culture.[97] This increase is independent of any direct influence on either phosphorylation or autophosphorylation[97] and distinct from that of chromodulin, which influences autophosphorylation.[43]

Some complexes with trivalent chromium have minor interactions with the insulin receptor, with complexes bound to small endogenous molecules such as histidinate, lactate, acetate or propionate showing minor inhibitory effects at concentrations around 100μM. Of these complexes, chromium-propionate appears to be more potent, showing inhibitory effects at concentrations as low as 1μM.[98]

Chromium itself has been implicated in enhancing insulin signalling, although the mechanism with chromium ions seems to differ from that seen with chromodulin and requires a significantly higher concentration. Chromium itself does not appear to directly influence the insulin receptor like chromodulin can.

Protein-tyrosine phosphatase 1B (PTP1B) is a negative regulator of insulin receptor signaling[99] that may be suppressed by endogenous chromium. Although chromodulin was found to activate membrane PTP activity in one earlier study,[100] there are many endogenous PTP enzymes, and PTP1B was not specifically examined in this study. Trivalent chromium has been shown to inhibit PTP1B by 21-33% in both rat and human hepatoma cells,[101] suggesting that chromium may potentiate insulin signaling by suppressing PTB1B-mediated dephosphorylation of the insulin receptor. In contrast, a more recent study noted that chromium failed to inhibit recombinant human PTP1B phosphatase activity in a pure in vitro system, suggesting that chromium may potentiate insulin signaling by mechanisms distinct from any effects on PTP1B.[97]

In an in vivo study, obese diabetic rats fed 80μg/kg chromium (as picolinate) experienced an overall decrease in PTP1B activity as well as protein expression which correlated with increased insulin signaling in skeletal muscle.[102] This decrease was not observed in lean rats given chromium at the same dose, however.[102]

Phosphorylation of IRS-1, an important transducer of insulin signaling that is inhibited by phosphorylation at Serine307,[103] is not affected by 10µM chromium in various trivalent forms.[98] Moreover, IRS protein expression remained unaffected with up to 80μg/kg chromium supplementation in rats.[102] In the absence of insulin however, basal IRS-1 signaling is slightly increased at 10µM chromium, which is thought to be due to decreased phosphorylation of Serine307[98] by Jun NH(2)-terminal kinase (JNK).[38] JNK negatively regulates IRS signaling via phosphorylation at Serine307,[103][104] which is increased in obese mice,[105][106] causing insulin resistance. Notably, JNK-mediated attenuation of insulin signaling in obese rats is suppressed by chromium.[105][106]

The above JNK activation could be traced back to endoplasmic reticulum (ER) stress in theory,[107] and agents that reduce ER stress also attenuate diabetic symptoms.[108][109] ER stress is known to be increased in cells from obese and diabetic animals and is treatable with chromium.[105]

Chromium interactions with PTP1B, a negative regulator of insulin receptor activity are not well-understood. Some studies suggest that chromium may not have appreciable effects on PTP1B signaling. It is possible, however, that chromium suppresses JNK-mediated attenuation of insulin signaling in the context of a pre-existing insulin resistant state.

Chromium does not appear to augment insulin receptor expression in the presence or absence of insulin, suggesting that its affects on insulin signaling occur independent of any changes in insulin receptor levels.[110][98] Moreover, when incubated with insulin, chromium does not affect the interaction of insulin with the insulin receptor.[97] This suggests that chromium does not affect insulin sensitivity via augmenting insulin receptor affinity.

Chromium does not affect insulin receptor expression levels or influence binding of insulin to the insulin receptor.

An early study conducted in 1992 revealed that chromium increases insulin internalization at 1µM (418ng/mL), which was associated with increased membrane fluidity and not replicated with other chelations of chromium or zinc picolinate.[111] The novel discovery that insulin is internalized into the cell was later revealed to be an important negative feedback mechanism for insulin receptor signaling. After insulin binds its receptor, the insulin-receptor complex is internalized by endocytosis,[112] triggering insulin degradation[113] and effectively reducing the number of insulin receptors displayed on the cell surface as a mechanism to attenuate the insulin response.[114]

After binding to its receptor outside the cell, insulin triggers movement of the insulin-receptor complex to inside the cell. This reduces the number of insulin receptors displayed on the cell surface and functions as a negative feedback mechanism to limit the insulin signaling response.


In response to an oral glucose tolerance test, supplementation of 200µg for eight weeks failed to increase the insulin response when measured after 10 minutes in type II diabetics[94] while 1,000µg (as picolinate) in non-diabetic persons with metabolic syndrome over 16 weeks has increased the insulin response despite no other change in diabetic biomarkers.[115]

7.4Insulin Sensitivity

One study noted that in spite of failure to find statistically significant improvements in insulin sensitivity for the whole group of subjects, 46% of subjects who also had higher baseline levels of insulin resistance improved by 10%.[56] Notably, there was no difference in the absorption or kinetics of chromium between responders and nonresponders,[56] suggesting that chromium supplementation may increase insulin sensitivity in the context of insulin resistance.

Moreover, supplementation of 1,000µg chromium (as picolinate) for 24 weeks in type II diabetics has been noted to slightly reduce intramuscular lipid concentrations relative to placebo.[56] Because buildup of lipids within muscle tissue is one of several pathological causes of insulin resistance,[116] this work further suggests that chromium supplementation may increase insulin sensitivity in those who are already insulin-resistant.

Chromium supplementation may promote improved insulin sensitivity in those who are already insulin-resistant.


A meta-analysis of trials in type II diabetics with over 250µg chromium supplementation lasting over three months failed to find any influence on HbA1c relative to placebo treatment.[92] This is in opposition to previous reviews assessing only trials in diabetics with a baseline HbA1c over 7%, where chromium supplementation resulted in a reduction in HbA1c by 0.34% relative to placebo.[117] Other reviews have noted reductions of 0.6%,[118] and as much as 0.9% when all forms of diabetes and insulin resistance were included.[119] It should be noted, however, that some of these analyses included trials lasting less than three months,[118] which may not be sufficient to measure authentic changes in HbA1c.[92]

Depending on the population studied and the type and quality of studies looked at, evidence that chromium affects hemoglobin A1C levels is mixed.

7.6Blood Glucose

Supplementation with 400 or 800µg chromium (as picolinate) alongside a test meal in otherwise healthy adults reduced glucose area under the curve (AUC) by 30-36% in responders, with the low-dose being more effective.[120] Notably, responders were classified by having a relatively lower meat and milk intake,[120] suggesting that chromium may affect postprandial glucose-metabolism in those with lower baseline levels of chromium. The reduction in glucose was not associated with any changes in insulin, excluding an insulinogenic effect, and occurred in persons without impaired glucose metabolism.[120]

Chromium supplementation may promote blood glucose-disposal, particularly in those with low dietary chromium intake.

In a meta-analysis of trials assessing chromium supplementation over 250µg in type II diabetics over a three month period (or longer),[92] the seven trials which were included in meta-analysis[56][89][121][122][123][124][125] failed to show a reduction in HbA1c levels in serum despite a mild reduction in blood glucose (RR of -0.95 and a 95% CI of -1.4 to -0.5).[92]

7.7Type 2 Diabetes

An analysis of observational data from the National Health and Nutrition Examination Survey (NHANES) found that people who consumed a dietary supplement containing chromium had a lower odds of having diabetes (OR = 0.73), defined by having an HbA1c level greater than 6.5. The use of supplements in general did not have a statistically significant effect on the odds of diabetes in this study.[126]

8Skeletal Muscle and Physical Performance


In studies pairing chromium with resistance training, chromium has failed to influence lean mass accrual in older persons (with a mean age around 60) after 13 weeks training while supplementing 1,000µg chromium picolinate.[127] In women around the same age and given the same protocol, chromium failed to affect body composition, strength or muscle fiber composition.[128] Another study investigating only older men reached similar conclusions in regards to the lack of effect of chromium supplementation on skeletal muscle.[129]

In youth wrestlers, 200µg chromium daily for 14 weeks failed to modify body composition or muscular performance.[130] Moreover, chromium supplementation at the same dose failed to have an effect on skeletal muscle in untrained people given a weight-training routine.[131]

Chromium does not seem to promote the growth of muscle mass in any population at any dose.

8.2Power Output

Chromium supplementation failed to increase power output in elderly women given 1,000µg chromium (as picolinate) over the course of 13 weeks.[128] Half this dose (500µg) in young female athletes similarly failed to increase power output.[132]

In young male wrestlers, 200µg chromium (as picolinate) over 14 weeks also failed to modify power output or muscular endurance.[130]

Chromium does not seem to affect power output in any population at any dose.

8.3Anaerobic Exercise Capacity

The addition of 400µg chromium (as picolinate) to a carbohydrate containing beverage prior to a shuttle run test in otherwise healthy and active men failed to modify the benefits of the carbohydrate containing beverage relative to water control, suggesting no additional benefits.[133]


One study using chromium (600µg as picolinate) daily for a month prior to a glycogen depletion exercise noted that immediately after exercise and for the next hour, the chromium group had significantly higher lactate levels relative to placebo.[134] In another study utilizing a shuttle-run exercise model, this increase in lactate failed to occur over 75 minutes of testing following consumption of 400µg chromium picolinate alongside carbohydrate or water control.[133] Moreover, lactate concentration at fatigue was similar in this study between both groups and water control.[133]

Results of studies examining the effect of chromium supplementation on lactate production are mixed, likely varying with the exercise model and sampling protocol. Taking the evidence into account, chromium does not appear to have a robust, meaningful effect on lactate production.


Glycogen synthase is the enzyme responsible for converting glucose to glycogen, the primary storage form of carbohydrate in the body. Likewise, glycogen phosphorylase is involved in breaking down these carbohydrate stores into glucose for energy. Because of its effects on glucose metabolism, chromium has been investigated for its impact on glycogen stores. Preliminary evidence revealed that rats fed chromium preserved liver glycogen better than a control group during fasting.[135] Later, it was noted that chromium increased the activity of the glycogen synthase enzyme in trained rat muscle and liver relative to nonsupplemental control, but glycogen phosphorylase was unaffected.[136]

Limited evidence in rats suggests that chromium supplementation can increase the storage and production of glycogen in skeletal muscle. Chromium does not seem to affect the breakdown of glycogen to free up glucose for energy, however.

In overweight and lightly trained or sedentary adults given supplementation of chromium (600µg as picolinate) daily for a month alongside a standardized diet with the last two days designed to deplete glycogen, supplementation failed to modify glycogen levels or the rate of resynthesis (from a carbohydrate containing beverage) relative to placebo.[134]

Chromium supplementation in overweight, untrained humans failed to affect glycogen resynthesis following exercise.

9Obesity and Fat Mass


According to a meta-analysis on weight in type II diabetics supplementing chromium (over 250µg) for over three months, there is no significant alteration in weight relative to placebo despite a modest reduction in blood glucose.[92] In contrast, another meta-analysis found that overweight and obese adults who supplemented with chromium picolinate reduced body weight in the dosage range of 200-1,000µg, regardless of diabetic status. Weight loss was very modest however, totaling only 1.1kg (95% CI in the range of 0.4-1.7kg).[137] Of note, this latter meta-analysis deemed the quality of evidence less than optimal, calling into question any chromium-mediated effects on weight loss.[137]

Chromium supplementation has little to no influence on weight. Although results from some studies are suggestive of very modest effect, robust, reliable evidence for weight loss is currently lacking.

One trial noted that weight gain associated with sulfonylurea therapy (0.9kg over 10 months) in diabetics was mitigated by coingestion of 1,000µg chromium.[124] Importantly, these results may be limited to those who are undergoing sulfonylurea therapy. When diabetic subjects who were not currently medicated were instructed to follow a weight-maintenance diet, 1,000µg chromium picolinate failed to modify food intake, appetite, or body weight.[56]

Chromium has also been used in an attempt to mitigate weight gain associated smoking cessation, as people who quit smoking often tend to gain a considerable amount of weight.[138] This trial used Hypericum perforatum (900mg) as the initial anti-smoking aid and then divided study subjects into chromium or placebo groups. Unfortunately, the trend for chromium to attenuate weight gain was unable to be tested with sufficient power, due to low success rates with the aforementioned herb. The effects of chromium were promising, however, possibly attenuating a 5.76 kg weight gain to 2.7 kg after six months).[1]

10Inflammation and Immunology


Certain trace minerals, as well as balance between different trace minerals, has been hypothesized to influence immune response. In postmenopausal women with high cholesterol, chromium supplementation (200μg daily for 12 weeks) failed to influence the counts of different immune cell types (lymphocytes, monocytes, neutrophils and eosinophils). However, proliferation of lymphocytes in response to mitogens (used as an indicator of immune function) was enhanced with chromium supplementation, which was ablated with copper at a dose of 3mg daily administered daily alongside chromium.[139]

11Interactions with Oxidation

11.1Lipid Peroxidation

Lipid peroxidation, a form of oxidation that causes oxidative damage to cellular membrane lipids, is identified by increased biomarkers such as TBARS and MDA. Increased lipid peroxidation is often associated with diabetes alongside increased HbA1c, a marker of dysfunctional glucose metabolism.[90] Thus, chromium has been investigated for its affect on lipid peroxidation alongside its role in glucose metabolism.

Chromium supplementation at 1,000µg daily for 6 months reduced lipid peroxidation as measured by a reduction in TBARS by 12-21% in people whose HbA1c exceeded 6.8%, independent of any changes in antioxidant enzyme levels (superoxide dismutase, catalase, glutathione peroxidase).[140] In people with normal HbA1c levels (below 6%), however, TBARS actually increased by 28.6%, suggesting that chromium acted as a pro-oxidant in this group.[140] In contrast, a reduction in TBARS of 13.6% without changes in antioxidant enzyme levels was noted in a study of diabetics after six months with 400µg of chromium.[141] Similar results were achieved with 30mg Zinc (as gluconate), which was mildly additive in patients given both chromium and zinc (reaching 18.6% with combination therapy).[141]

Chromium may reduce lipid peroxidation in certain populations. More studies are needed, however, to determine the appropriate dose as well as who may benefit.

11.2DNA Damage

Chromium (as trivalent picolinate) has been shown to induce chromosomal damage in chinese hamster ovary (CHO) cells at concentrations of 50µM or greater, although this damage is thought to be caused by the picolinate ligands and not the chromium itself, since other forms of chromium failed to induce damage.[142] Other trivalent chromium complexes have been noted to cause DNA strand breaks, however,[21][143] albeit at a much higher concentration than the toxic hexavalent form.[144] It is thought that the DNA strand breaks are caused by CrIII being reduced to CrII, which can then be oxidized back to CrIII in a process which creates pro-oxidants that damage DNA.[27][145]

Chromodulin, the peptide which contains chromium, does not appear to damage DNA nor does it appear to release free chromium under physiologically relevant conditions.[146]

Daily supplementation with 400µg chromium (as picolinate) for eight weeks in obese women failed to alter levels of the anti-HMdU (5-hydroxymethyl-2'-deoxyuridine) antibody in titers,[147] an oxidized DNA base and indicator of DNA damage.[148] This lack of increase was reported to demonstrate absence of genotoxicity.[147]

Chromium picolinate, more than other trivalent forms of chromium, has the ability to form prooxidants that can potentially cause DNA damage. The relevance to standard oral supplementation is not known, since the concentration required to damage DNA (in upwards of 50µM) is significantly higher than what is seen in the blood following oral ingestion of supplements. Moreover, studies in human subjects have failed to note DNA damage with standard supplemental doses.

12Peripheral Organ Systems

12.1Male Sex Organs

The concentration of chromium in the testes of diabetic rats (0.36µg/g dry weight) is less than that of control rats (0.63µg/g).[149] Injections of trivalent chromium at a dose of 500µg/kg bodyweight for three days can be detected in the testicular tissue of both normal and diabetic rats, with most of the accumulation occurring in the cytosol (with minimal accumulation in the nucleus, mitochondria, lysosome, or microsomes). This asymmetrical accumulation occurs despite the fact that chromium losses asscoated with diabetes occur in all subfractions of the cell.[149]

Hexavalent chromium, the form used in industries but not supplementation, is known to be toxic to testicular tissue.[150][151] In contrast, high concentrations of trivalent chromium (up to 1mM) have failed to suppress cellular proliferation of sertoli-like cells,[152] suggesting a lack of apparent toxicity.

Chromium accumulates in the testes of rats when injected, although the possible benefits or harm in the testicles with oral supplementation of chromium have not been studied. Hexavalent chromium, the toxic form not found in supplements, is known to be toxic to the testes.

13Sexuality and Pregnancy


Chromium was found to be present in breast milk at concentrations of 1.73–8.85nM in one study[153] with other studies finding similar results.[154][155][156][157] Acute supplementation of chromium (400µg as trichloride once daily for three days) does not appear to significantly influence breast milk chromium concentrations despite appearing in serum.[153] This lack of correlation with serum chromium has been reported previously,[155] suggesting that breast milk chromium is more reflective of chronic chromium status and, unlike the blood, tightly regulated against acute fluctuations.

Chromium intake of lactating women, without prompting to consume chromium, tends to be greater than that of age-matched female controls.[157][155]

14Other Medical Conditions


Supplementation of 400µg chromium as picolinate (a dose suggested to hinder 5-HT2A signalling[73] thereby acting as an antipsychotic[158]) to persons with schizophrenia on stable medication failed to provide any benefits over three months as assessed by PANSS or the HAM-D rating scales.[159]

14.2Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a syndrome associated with insulin resistance due to high androgen levels in women, A preliminary study in five women given 470µg chromium (as picolinate) twice daily for two months noted a significant increase in glucose disposal rates of 38% and a trend to reduce insulin levels, suggesting improved insulin sensitivity.[160]

A double-blind, placebo-controlled study using 200 µg chromium picolinate supplementation for 8 weeks found significant decreases in plasma insulin levels and improved insulin sensitivity in women with PCOS. There was also a trend toward improved lipid profiles, although none of the differences were statistically significant.[161] Another such study also using 200 µg chromium picolinate for 8 weeks found reduced acne, hirsutism, and C-reactive protein and improved plasma total antioxidant capacity but no change in reproductive hormones (FSH, LH, prolactin, and free testosterone).[162]

Chromium supplementation may improve some symptoms and the metabolic profile of women with polycystic ovarian syndrome, although no impact on reproductive hormone levels has been found.

15Nutrient-Nutrient Interactions


Chromium ingestion at 400µg (as picolinate) failed to influence baseline cortisol levels, but does reduce the increase caused by 5-HTP administration.[73] The authors of the study discovering this suggested that this effect due to desensitization by chromium of the 5-HT2A receptor, which mediates cortisol levels.[73]


Chromium is known to be transported in the blood with the same transporter that carries iron and some other dietary minerals, known as transferrin.[59] Minerals in general may be competitive at this level,[163] and high levels of chromium given to rats (1,000µg/kg for 45 days) have been noted to reduce total iron binding capacity (11%) and serum iron (28%) via competitive inhibition.[164] This has led to the investiagtion of the potential for chromium to reduce iron status in humans.

One study noted that supplementation of a low dose of chromium (187µg as picolinate) over a 12 week period does not influence total iron binding capacity of the blood or iron status of otherwise healthy women.[165] Another study found that eight weeks of supplementation of 500µg chromium via Brewer's yeast failed to alter serum or hair concentrations of iron (and other minerals, such as copper and zinc) despite an increase of chromium in serum (116%) and in hair (20.6%).[166] These results are suggestive that chromium supplementation at low levels does not affect iron status in humans.

Although studies in rats taking very high doses of chromium have suggested that chromium may interfere with iron transport, human studies of chromium supplementation at normal doses have not demonstrated this. It seems that chromium supplementation at normal dosing has no effect on iron state in humans.

15.3Grape Seed Extract

Grape seed extract (GSE) is a source of procyanidins (similar to pycnogenol) that is claimed to have cardioprotective effects, and it has been investigated in conjunction with chromium supplementation. It has been hypothesized[167] that the cardiovascular benefits of this combination are secondary to interactions between insulin sensitizers (in this case, chromium) and antioxidants (GSE), since diseases characterized by insulin resistance also have high free radical production.[168] 

One pilot study assessing the combination found a decrease in total cholesterol with the combination of 200µg chromium (as polynicotinate) paired with 100mg GSE that was not present in either group alone[35] while a reduction in LDL oxidation seemed to be mostly due to GSE with no contribution from chromium.[35]

GSE and chromium are speculated to be additive or synergistic in alleviating the signs of metabolic syndrome, but at this moment the evidence to support synergism is limited.


Inositol is an insulin-sensitizing sugar is used as a dietary supplement, and could in principle be complementary with chromium due to their similar uses.

In older sedentary adults, 924µg chromium (as picolinate) daily for 13 weeks alongside resistance training and a controlled diet (given to both chromium and placebo groups) has failed to influence either total urinary inositols or the ratio of myo-inositol:D-chiro-inositol.[169]

16Safety and Toxicity


Two months ingestion of chromium (nanoparticles of picolinate) at 600-1,000µg/kg food intake in rats failed to demonstrate any organ damage or modification of H2O2-induced DNA damage in mouse hepatocytes in vitro.[170] Higher doses of chromium (as either chloride or picolinate) up to 100mg/kg failed to show organ damage to the kidneys or liver and induced no abnormalities in blood parameters.[171] Elsewhere, chromium (1-100µg/g food intake or 1-100mg/kg) has been noted to elevate liver enzymes associated with a low liver weight in rats despite no histopathological changes, and these changes were more significant with picolinate (relative to chloride).[63] 

It was suggested that a dietary intake of chromium of 100mg/kg of food was approximately an equal to an intake of 10mg/kg body weight,[63] and since minor increases in liver enzymes were noted at 1mg/kg in the rat diet (or 100µg/kg in relation to bodyweight) it suggests that adverse effects could occur in humans above this dose.[63]

In rats, liver damage appears to be able to be induced with an intake of chromium which is above recommended supplemental levels.

16.2Case Studies

There is a case study of a woman ingesting 1200-2400 µg chromium (as picolinate) for 4-5 months who exhibited symptoms of renal damage[172] and one case of a bodybuilder who developed rhabdomyolysis associated with 1,200 µg over the course of two days.[173]


  1. ^ a b Parsons A, et al. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation. Drug Alcohol Depend. (2009)
  2. ^ a b c d Lukaski HC. Chromium as a supplement. Annu Rev Nutr. (1999)
  3. ^ a b c Yamamoto A, Wada O, Suzuki H. Purification and properties of biologically active chromium complex from bovine colostrum. J Nutr. (1988)
  4. ^ Yamamoto A, Wada O, Suzuki H. Separation of biologically active chromium complex from cow colostrum. Tohoku J Exp Med. (1987)
  5. ^ a b Hexavalent Chromium.
  6. ^ a b c Trumbo P, et al. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc. (2001)
  7. ^ Iyengar V, Woittiez J. Trace elements in human clinical specimens: evaluation of literature data to identify reference values. Clin Chem. (1988)
  8. ^ a b Freund H, Atamian S, Fischer JE. Chromium deficiency during total parenteral nutrition. JAMA. (1979)
  9. ^ a b Jeejeebhoy KN, et al. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr. (1977)
  10. ^ Davies S, et al. Age-related decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients--implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabolism. (1997)
  11. ^ Sundararaman PG, et al. Serum chromium levels in gestational diabetes mellitus. Indian J Endocrinol Metab. (2012)
  12. ^ Woods SE, et al. Serum chromium and gestational diabetes. J Am Board Fam Med. (2008)
  13. ^ Kozlovsky AS, et al. Effects of diets high in simple sugars on urinary chromium losses. Metabolism. (1986)
  14. ^ Hajifaraji M, Leeds AR. The effect of high and low glycemic index diets on urinary chromium in healthy individuals: a cross-over study. Arch Iran Med. (2008)
  15. ^ a b c d Vincent JB. The biochemistry of chromium. J Nutr. (2000)
  16. ^ Davis CM, Vincent JB. Isolation and characterization of a biologically active chromium oligopeptide from bovine liver. Arch Biochem Biophys. (1997)
  17. ^ a b Clodfelder BJ, et al. The trail of chromium(III) in vivo from the blood to the urine: the roles of transferrin and chromodulin. J Biol Inorg Chem. (2001)
  18. ^ Anderson RA, et al. Urinary chromium excretion of human subjects: effects of chromium supplementation and glucose loading. Am J Clin Nutr. (1982)
  19. ^ a b Anderson RA, et al. Effect of Exercise (Running) on Serum Glucose, Insulin, Glucagon, and Chromium Excretion. Diabetes. (1982)
  20. ^ Wahren J, et al. Glucose metabolism during leg exercise in man. J Clin Invest. (1971)
  21. ^ a b Bagchi D, et al. Comparative induction of oxidative stress in cultured J774A.1 macrophage cells by chromium picolinate and chromium nicotinate. Res Commun Mol Pathol Pharmacol. (1997)
  22. ^ Wise SS, Holmes AL, Wise JP Sr. Hexavalent chromium-induced DNA damage and repair mechanisms. Rev Environ Health. (2008)
  23. ^ Zhang XH, et al. Chronic occupational exposure to hexavalent chromium causes DNA damage in electroplating workers. BMC Public Health. (2011)
  24. ^ Kingry KF, Royer AC, Vincent JB. Nuclear magnetic resonance studies of chromium(III) pyridinecarboxylate complexes. J Inorg Biochem. (1998)
  25. ^ Stearns DM, Armstrong WH. Mononuclear and binuclear chromium(III) picolinate complexes. Inorg Chem. (1992)
  26. ^ Yuen G, Heaster H, Hoggard PE. Amine spectrochemical properties in tris(aminocarboxylate) complexes of chromium(III). Inorg Chim Acta. (1983)
  27. ^ a b c Speetjens JK, et al. The nutritional supplement chromium(III) tris(picolinate) cleaves DNA. Chem Res Toxicol. (1999)
  28. ^ Raspor P, et al. The influence of chromium compounds on yeast physiology (a review). Acta Microbiol Immunol Hung. (2000)
  29. ^ Pas M, et al. Uptake of chromium(III) and chromium(VI) compounds in the yeast cell structure. Biometals. (2004)
  30. ^ a b Grant AP, McMullen JK. The effect of brewers yeast containing glucose tolerance factor on the response to treatment in Type 2 diabetics. A short controlled study. Ulster Med J. (1982)
  31. ^ Schwarz K, Mertz W. A glucose tolerance factor and its differentiation from factor 3. Arch Biochem Biophys. (1957)
  32. ^ Mirsky N, Weiss A, Dori Z. Chromium in biological systems, I. Some observations on glucose tolerance factor in yeast. J Inorg Biochem. (1980)
  33. ^ Weksler-Zangen S, et al. Glucose tolerance factor extracted from yeast: oral insulin-mimetic and insulin-potentiating agent: in vivo and in vitro studies. Br J Nutr. (2012)
  34. ^ Toepfer EW, et al. Preparation of chromium-containing material of glucose tolerance factor activity from brewer's yeast extracts and by synthesis. J Agric Food Chem. (1976)
  35. ^ a b c d Preuss HG, et al. Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. J Med. (2000)
  36. ^ a b Thomas VL, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res. (1996)
  37. ^ Jain SK, et al. Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-α, oxidative stress, and insulin resistance in type 2 diabetic subjects: randomized, double-blind, placebo-controlled study. Mol Nutr Food Res. (2012)
  38. ^ a b Hua Y, et al. Molecular mechanisms of chromium in alleviating insulin resistance. J Nutr Biochem. (2012)
  39. ^ a b Yamamoto A, Wada O, Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem. (1987)
  40. ^ a b Vincent JB. Quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr Rev. (2000)
  41. ^ Yamamoto A, Wada O, Ono T. A low-molecular-weight, chromium-binding substance in mammals. Toxicol Appl Pharmacol. (1981)
  42. ^ a b Chen Y, et al. Characterization of the organic component of low-molecular-weight chromium-binding substance and its binding of chromium. J Nutr. (2011)
  43. ^ a b c Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry. (1997)
  44. ^ a b Yamamoto A, Wada O, Manabe S. Evidence that chromium is an essential factor for biological activity of low-molecular-weight, chromium-binding substance. Biochem Biophys Res Commun. (1989)
  45. ^ a b Myers MG Jr, White MF. The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes. (1993)
  46. ^ Vincent JB. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc. (2004)
  47. ^ Vincent JB. Chromium: celebrating 50 years as an essential element. Dalton Trans. (2010)
  48. ^ Rutter GA, Da Silva Xavier G, Leclerc I. Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J. (2003)
  49. ^ Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. (2011)
  50. ^ Zhao P, et al. A newly synthetic chromium complex-chromium (D-phenylalanine)3 activates AMP-activated protein kinase and stimulates glucose transport. Biochem Pharmacol. (2009)
  51. ^ a b Anderson RA, Kozlovsky AS. Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr. (1985)
  52. ^ Bunker VW, et al. The uptake and excretion of chromium by the elderly. Am J Clin Nutr. (1984)
  53. ^ a b Chen NS, Tsai A, Dyer IA. Effect of chelating agents on chromium absorption in rats. J Nutr. (1973)
  54. ^ Hahn CJ, Evans GW. Absorption of trace metals in the zinc-deficient rat. Am J Physiol. (1975)
  55. ^ Laschinsky N, et al. Bioavailability of chromium(III)-supplements in rats and humans. Biometals. (2012)
  56. ^ a b c d e f g h Cefalu WT, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism. (2010)
  58. ^ Ainscough EW, et al. Studies on human lactoferrin by electron paramagnetic resonance, fluorescence, and resonance Raman spectroscopy. Biochemistry. (1980)
  59. ^ a b Aisen P, Aasa R, Redfield AG. The chromium, manganese, and cobalt complexes of transferrin. J Biol Chem. (1969)
  60. ^ a b Sun Y, et al. The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr. J Biol Inorg Chem. (2000)
  61. ^ a b Yamamoto A, Wada O, Ono T. Distribution and chromium-binding capacity of a low-molecular-weight, chromium-binding substance in mice. J Inorg Biochem. (1984)
  62. ^ Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. (1983)
  63. ^ a b c d Yoshida M, et al. Tissue accumulation and urinary excretion of chromium in rats fed diets containing graded levels of chromium chloride or chromium picolinate. J Toxicol Sci. (2010)
  64. ^ Seal CJ, Heaton FW. Effect of dietary picolinic acid on the metabolism of exogenous and endogenous zinc in the rat. J Nutr. (1985)
  65. ^ a b McCarty MF. Longevity effect of chromium picolinate--'rejuvenation' of hypothalamic function. Med Hypotheses. (1994)
  66. ^ Evans GW. Chromium picolinate is an efficacious and safe supplement. Int J Sport Nutr. (1993)
  67. ^ Mertz W. Chromium occurrence and function in biological systems. Physiol Rev. (1969)
  68. ^ Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes. (1980)
  69. ^ Offenbacher EG, Rinko CJ, Pi-Sunyer FX. The effects of inorganic chromium and brewer's yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects. Am J Clin Nutr. (1985)
  70. ^ a b c d Franklin M, Odontiadis J. Effects of treatment with chromium picolinate on peripheral amino acid availability and brain monoamine function in the rat. Pharmacopsychiatry. (2003)
  71. ^ McCarty MF. Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression--an adjuvant role for chromium picolinate. Med Hypotheses. (1994)
  72. ^ Hainer V, et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann N Y Acad Sci. (2006)
  73. ^ a b c d e f g Attenburrow MJ, et al. Chromium treatment decreases the sensitivity of 5-HT2A receptors. Psychopharmacology (Berl). (2002)
  74. ^ Horácek J, et al. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology. (1999)
  75. ^ Palazidou E, et al. Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol Med. (1992)
  76. ^ Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord. (2003)
  77. ^ a b Docherty JP, et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract. (2005)
  78. ^ a b c Anton SD, et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technol Ther. (2008)
  79. ^ Singh T, Williams K. Atypical depression. Psychiatry (Edgmont). (2006)
  80. ^ Brownley KA, et al. A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study. J Psychosom Res. (2013)
  81. ^ a b c Krikorian R, et al. Improved cognitive-cerebral function in older adults with chromium supplementation. Nutr Neurosci. (2010)
  82. ^ Amann BL, et al. A 2-year, open-label pilot study of adjunctive chromium in patients with treatment-resistant rapid-cycling bipolar disorder. J Clin Psychopharmacol. (2007)
  83. ^ McLeod MN, Gaynes BN, Golden RN. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry. (1999)
  84. ^ a b Davidson JR, et al. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry. (2003)
  85. ^ Guallar E, et al. Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol. (2005)
  86. ^ a b Vrtovec M, et al. Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. Am Heart J. (2005)
  87. ^ Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes. (2003)
  88. ^ Okin PM, et al. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes. (2004)
  89. ^ a b Ghosh D, et al. Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem. (2002)
  90. ^ a b Jain SK, et al. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes. (1989)
  91. ^ Jain SK, et al. Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes. Antioxid Redox Signal. (2006)
  92. ^ a b c d e f g Abdollahi M, et al. Effect of chromium on glucose and lipid profiles in patients with type 2 diabetes; a meta-analysis review of randomized trials. J Pharm Pharm Sci. (2013)
  93. ^ Gastaldelli A, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes. (2000)
  94. ^ a b c Pei D, et al. The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Metabolism. (2006)
  95. ^ a b Wu GY, Wada O. Studies on a specific chromium binding substance (a low-molecular-weight chromium binding substance) in urine (author's transl). Sangyo Igaku. (1981)
  96. ^ Wada O, et al. Low-molecular-weight, chromium-binding substance in rat lungs and its possible role in chromium movement. Ind Health. (1983)
  97. ^ a b c d Wang H, Kruszewski A, Brautigan DL. Cellular chromium enhances activation of insulin receptor kinase. Biochemistry. (2005)
  98. ^ a b c d Mackowiak P, et al. Evaluation of insulin binding and signaling activity of newly synthesized chromium(III) complexes in vitro. Mol Med Rep. (2010)
  99. ^ Ukkola O, Santaniemi M. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities. J Intern Med. (2002)
  100. ^ Davis CM, Sumrall KH, Vincent JB. A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). Biochemistry. (1996)
  101. ^ Goldstein BJ, et al. Enhancement of post-receptor insulin signaling by trivalent chromium in hepatoma cells is associated with differential inhibition of specific protein-tyrosine phosphatases. J Trace Elem Exp Med. (2001)
  102. ^ a b c Wang ZQ, et al. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr. (2006)
  103. ^ a b Aguirre V, et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. (2000)
  104. ^ Solinas G, et al. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A. (2006)
  105. ^ a b c Sreejayan N, et al. Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity (Silver Spring). (2008)
  106. ^ a b Chen WY, et al. Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice. Diabetes Obes Metab. (2009)
  107. ^ Ozcan U, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. (2004)
  108. ^ Engin F, Hotamisligil GS. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes Metab. (2010)
  109. ^ Ozcan U, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. (2006)
  110. ^ Yang X, et al. Insulin-sensitizing and cholesterol-lowering effects of chromium (D-Phenylalanine)3. J Inorg Biochem. (2006)
  111. ^ Evans GW, Bowman TD. Chromium picolinate increases membrane fluidity and rate of insulin internalization. J Inorg Biochem. (1992)
  112. ^ Gorden P, et al. Intracellular translocation of iodine-125-labeled insulin: direct demonstration in isolated hepatocytes. Science. (1978)
  113. ^ McClain DA. Mechanism and role of insulin receptor endocytosis. Am J Med Sci. (1992)
  114. ^ Geiger D, et al. Down-regulation of insulin receptors is related to insulin internalization. Exp Cell Res. (1989)
  115. ^ Iqbal N, et al. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord. (2009)
  116. ^ Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. (2006)
  117. ^ Patal PC, Cardino MT, Jimeno CA. A meta-analysis on the effect of chromium picolinate on glucose and lipid profiles among patients with type 2 diabetes mellitus. Philipp J Intern Med. (2010)
  118. ^ a b Balk EM, et al. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care. (2007)
  119. ^ Broadhurst CL, Domenico P. Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review. Diabetes Technol Ther. (2006)
  120. ^ a b c Frauchiger MT, Wenk C, Colombani PC. Effects of acute chromium supplementation on postprandial metabolism in healthy young men. J Am Coll Nutr. (2004)
  121. ^ Kleefstra N, et al. Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care. (2007)
  122. ^ Kleefstra N, et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care. (2006)
  123. ^ Lai MH. Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and e supplementation for type 2 diabetes mellitus. J Clin Biochem Nutr. (2008)
  124. ^ a b Martin J, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. (2006)
  125. ^ Racek J, et al. Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol Trace Elem Res. (2006)
  126. ^ McIver DJ, et al. Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements. J Nutr. (2015)
  127. ^ Joseph LJ, et al. Effect of resistance training with or without chromium picolinate supplementation on glucose metabolism in older men and women. Metabolism. (1999)
  128. ^ a b Campbell WW, et al. Effects of resistive training and chromium picolinate on body composition and skeletal muscle size in older women. Int J Sport Nutr Exerc Metab. (2002)
  129. ^ Campbell WW, et al. Effects of resistance training and chromium picolinate on body composition and skeletal muscle in older men. J Appl Physiol (1985). (1999)
  130. ^ a b Walker LS, et al. Chromium picolinate effects on body composition and muscular performance in wrestlers. Med Sci Sports Exerc. (1998)
  131. ^ Hallmark MA, et al. Effects of chromium and resistive training on muscle strength and body composition. Med Sci Sports Exerc. (1996)
  132. ^ Livolsi JM, Adams GM, Laguna PL. The effect of chromium picolinate on muscular strength and body composition in women athletes. J Strength Cond Res. (2001)
  133. ^ a b c Davis JM, Welsh RS, Alerson NA. Effects of carbohydrate and chromium ingestion during intermittent high-intensity exercise to fatigue. Int J Sport Nutr Exerc Metab. (2000)
  134. ^ a b Volek JS, et al. Effects of chromium supplementation on glycogen synthesis after high-intensity exercise. Med Sci Sports Exerc. (2006)
  135. ^ Roginski EE, Mertz W. Effects of Chromium (III) Supplementation on Glucose and Amino Acid Metabolism in Rats Fed a Low Protein Diet. J Nutr.
  136. ^ Campbell WW, et al. Exercise training and dietary chromium effects on glycogen, glycogen synthase, phosphorylase and total protein in rats. J Nutr. (1989)
  137. ^ a b Tian H, et al. Chromium picolinate supplementation for overweight or obese adults. Cochrane Database Syst Rev. (2013)
  138. ^ Meyers AW, et al. Are weight concerns predictive of smoking cessation? A prospective analysis. J Consult Clin Psychol. (1997)
  139. ^ Rhee YS, et al. The effects of chromium and copper supplementation on mitogen-stimulated T cell proliferation in hypercholesterolaemic postmenopausal women. Clin Exp Immunol. (2002)
  140. ^ a b Cheng HH, et al. Antioxidant effects of chromium supplementation with type 2 diabetes mellitus and euglycemic subjects. J Agric Food Chem. (2004)
  141. ^ a b Anderson RA, et al. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr. (2001)
  142. ^ Stearns DM, et al. Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J. (1995)
  143. ^ Parand A, et al. DNA nicking by a trinuclear chromium complex. Inorg. Chim. Acta. (1998)
  144. ^ Hassoun EA, Stohs SJ. Chromium-induced production of reactive oxygen species, DNA single-strand breaks, nitric oxide production, and lactate dehydrogenase leakage in J774A.1 cell cultures. J Biochem Toxicol. (1995)
  145. ^ Sugden KD, Geer RD, Rogers SJ. Oxygen radical-mediated DNA damage by redox-active Cr(III) complexes. Biochemistry. (1992)
  146. ^ Speetjens JK, et al. Low-molecular-weight chromium-binding substance and biomimetic {Cr3O(O2CCH2CH3)6(H2O)3}+ do not cleave DNA under physiologically-relevant conditions. Polyhedron. (1999)
  147. ^ a b Kato I, et al. Effect of supplementation with chromium picolinate on antibody titers to 5-hydroxymethyl uracil. Eur J Epidemiol. (1998)
  148. ^ Shirnamé-Moré L, et al. Genetic effects of 5-hydroxymethyl-2'-deoxyuridine, a product of ionizing radiation. Mutat Res. (1987)
  149. ^ a b Feng W, et al. Tissue contents and subcellular distribution of chromium and other trace metals in experimental diabetic rats after intravenous injection of Cr 50-enriched stable isotopic tracer solution. Metabolism. (2001)
  150. ^ Marouani N, et al. Effects of hexavalent chromium on reproductive functions of male adult rats. Reprod Biol. (2012)
  151. ^ Carette D, et al. Hexavalent chromium at low concentration alters Sertoli cell barrier and connexin 43 gap junction but not claudin-11 and N-cadherin in the rat seminiferous tubule culture model. Toxicol Appl Pharmacol. (2013)
  152. ^ Cheng RY, et al. Microarray analysis of altered gene expression in the TM4 Sertoli-like cell line exposed to chromium(III) chloride. Reprod Toxicol. (2002)
  153. ^ a b Mohamedshah FY, et al. Distribution of a stable isotope of chromium (53Cr) in serum, urine, and breast milk in lactating women. Am J Clin Nutr. (1998)
  154. ^ Kumpulainen J, et al. Dietary chromium intake of lactating Finnish mothers: effect on the Cr content of their breast milk. Br J Nutr. (1980)
  155. ^ a b c Anderson RA, et al. Breast milk chromium and its association with chromium intake, chromium excretion, and serum chromium.. Am J Clin Nutr. (1993)
  156. ^ Kumpulainen J, Vuori E. Longitudinal study of chromium in human milk.. Am J Clin Nutr. (1980)
  157. ^ a b Casey CE, Hambidge KM. Chromium in human milk from American mothers. Br J Nutr. (1984)
  158. ^ Mestre TA, Zurowski M, Fox SH. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. Expert Opin Investig Drugs. (2013)
  159. ^ Hockney RA, et al. Lack of effect of chromium supplementation on mental state and body weight in people with schizophrenia. J Clin Psychopharmacol. (2006)
  160. ^ Lydic ML, et al. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril. (2006)
  161. ^ Jamilian M, Asemi Z. Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Nutr Metab. (2015)
  162. ^ Jamilian M, et al. The Effects of Chromium Supplementation on Endocrine Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. (2016)
  163. ^ Yang J, Black J. Competitive binding of chromium, cobalt and nickel to serum proteins. Biomaterials. (1994)
  164. ^ Ani M, Moshtaghie AA. The effect of chromium on parameters related to iron metabolism. Biol Trace Elem Res. (1992)
  165. ^ Lukaski HC, Siders WA, Penland JG. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. Nutrition. (2007)
  166. ^ Król E, et al. Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol Trace Elem Res. (2011)
  167. ^ Preuss HG, Bagchi D, Bagchi M. Protective effects of a novel niacin-bound chromium complex and a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome X. Ann N Y Acad Sci. (2002)
  168. ^ Diplock AT. Antioxidant nutrients and disease prevention: an overview. Am J Clin Nutr. (1991)
  169. ^ Campbell WW, et al. Resistive training and chromium picolinate: effects on inositols and liver and kidney functions in older adults. Int J Sport Nutr Exerc Metab. (2004)
  170. ^ Chen SY, Lien TF. Toxicity evaluation of chromium picolinate nanoparticles in vivo and in vitro in rat. Biol Trace Elem Res. (2013)
  171. ^ Anderson RA, Bryden NA, Polansky MM. Lack of toxicity of chromium chloride and chromium picolinate in rats. J Am Coll Nutr. (1997)
  172. ^ Cerulli J, et al. Chromium picolinate toxicity. Ann Pharmacother. (1998)
  173. ^ Martin WR, Fuller RE. Suspected chromium picolinate-induced rhabdomyolysis. Pharmacotherapy. (1998)
  174. Bahijiri SM, et al. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J. (2000)
  175. Anderson RA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. (1997)
  176. Kim CW, et al. Effects of short-term chromium supplementation on insulin sensitivity and body composition in overweight children: randomized, double-blind, placebo-controlled study. J Nutr Biochem. (2011)
  177. Feiner JJ, et al. Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study. Diabetes Obes Metab. (2008)
  178. Gunton JE, et al. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care. (2005)
  179. Paiva AN, et al. Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: A randomized clinical study. J Trace Elem Med Biol. (2015)
  180. Yazaki Y, et al. A pilot study of chromium picolinate for weight loss. J Altern Complement Med. (2010)
  181. Ali A, et al. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract. (2011)
  182. Sharma S, et al. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J Trace Elem Med Biol. (2011)
  183. Aghdassi E, et al. In patients with HIV-infection, chromium supplementation improves insulin resistance and other metabolic abnormalities: a randomized, double-blind, placebo controlled trial. Curr HIV Res. (2010)
  184. Brownley KA, et al. Chromium supplementation for menstrual cycle-related mood symptoms. J Diet Suppl. (2013)